-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Insmed, Lowers Price Target to $230

Benzinga·12/18/2025 16:52:12
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $240 to $230.